| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9884044 | EAGLE PHARMS | Treatment using dantrolene |
Jun, 2022
(1 year, 10 months ago) | |
| US8604072 | EAGLE PHARMS | Treatment using dantrolene |
Jul, 2022
(1 year, 9 months ago) | |
| US8110225 | EAGLE PHARMS | Treatment using dantrolene |
Dec, 2022
(1 year, 4 months ago) | |
| US8685460 | EAGLE PHARMS | Treatment using dantrolene |
Feb, 2023
(1 year, 2 months ago) | |
| US7758890 | EAGLE PHARMS | Treatment using dantrolene |
Jun, 2025
(1 year, 2 months from now) | |
Ryanodex is owned by Eagle Pharms.
Ryanodex contains Dantrolene Sodium.
Ryanodex has a total of 5 drug patents out of which 4 drug patents have expired.
Expired drug patents of Ryanodex are:
- US9884044
- US8604072
- US8110225
- US8685460
Ryanodex was authorised for market use on 22 July, 2014.
Ryanodex is available in for suspension;intravenous dosage forms.
Ryanodex can be used as for use in the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk..
The generics of Ryanodex are possible to be released after 30 June, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 22, 2021 |
| Orphan Drug Exclusivity(ODE-69) | Jul 22, 2021 |
Drugs and Companies using DANTROLENE SODIUM ingredient
Market Authorisation Date: 22 July, 2014
Treatment: For use in the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.
Dosage: FOR SUSPENSION;INTRAVENOUS
RYANODEX family patents
